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Studies reporting on biomarkers aiming to predict adverse renal outcomes in patients with type 2 
diabetes and kidney disease (DKD) conventionally define a surrogate endpoint either as a percentage 
of decrease of eGFR (e.g. ≥ 30%) or an absolute decline (e.g. ≥ 5 ml/min/year). The application of those 
study results in clinical practise however relies on the assumption of a linear and intra‑individually 
stable progression of DKD. We studied 860 patients of the PROVALID study and 178 of an independent 
population with a relatively preserved eGFR at baseline and at least 5 years of follow up. Individuals 
with a detrimental prognosis were identified using various thresholds of a percentage or absolute 
decline of eGFR after each year of follow up. Next, we determined how many of the patients met 
the same criteria at other points in time. Interindividual eGFR decline was highly variable but in 
addition intra‑individual eGFR trajectories also were frequently non‑linear. For example, of all 
subjects reaching an endpoint defined as a decrease of eGFR by ≥ 30% between baseline and 3 years 
of follow up, only 60.3 and 45.2% lost at least the same amount between baseline and year 4 or 5. The 
results were similar when only patients on stable medication or subpopulations based on baseline 
eGFR or albuminuria status were analyzed or an eGFR decline of ≥ 5 ml/min/1.73m2/year was used. 
Identification of reliable biomarkers predicting adverse prognosis is a strong clinical need given 
the large interindividual variability of DKD progression. However, it is conceptually challenging in 
early DKD because of non‑linear intra‑individual eGFR trajectories. As a result, the performance of a 
prognostic biomarker may be accurate after a specific time of follow‑up in a single population only.
Type 2 diabetes mellitus associated renal disease (diabetic kidney disease, DKD) is a serious public health 
problem and the leading cause of end stage renal disease (ESRD) in developed  countries1,2. Nonetheless, when 
considering the large and continuously increasing number of patients at risk, only a fraction ultimately requires 
renal replacement  therapy3. One explanation is the excessive competing risk of (mostly cardiovascular)  mortality4, 
which increases in parallel to the decline in estimated glomerular filtration rate (eGFR)5. In addition, not all 
patients develop  DKD6–8 and even those who do, progress at a highly variable  rate9. The KDIGO guidelines 
suggest using eGFR and urinary albumin excretion (UAE) for cross sectional categorization of chronic kidney 
disease into 5 eGFR and 3 UAE  stages10. On a cohort level this also provides reasonable information about the 
risk of DKD progression, defined by KDIGO either as a drop in eGFR category and a decline by at least 25% 
in eGFR or a loss of ≥ 5 ml/min/year/1.73m210. However, personalized medicine mandates a more accurate 
risk prediction on the level of an  individual11–13. In clinical practice this could trigger targeted therapy with an 
increased chance of success and/or a reduction of side  effects14. Furthermore, recruitment of high-risk subjects 
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into interventional studies at least theoretically allows decreasing the number of patients (and costs) necessary 
to reach statistically solid  conclusions15.
Biomarkers are potentially excellent tools for describing subpopulations/individuals with different progres-
sion characteristics. Given the high clinical need and massive research activities invested, it is surprising that 
accurate prediction of prognosis in clinical practice is still difficult especially in early DKD and very few markers 
have undergone successful confirmatory testing in independent cohorts.
During the last decades it became evident that the pathophysiology of DKD is  complex16. Next to systemic 
co-morbidities or effects of medication, the cross-sectional inter-17, and longitudinal intra-individual18 variability 
of pathways driving the disease leads to an unstable course over  time9. This not only challenges the concept of 
a linear trajectory of eGFR decline but also conceptually creates a dilemma for biomarker research. To identify 
prognostic classifiers, observational or interventional studies are used, which follow patients for a specific period 
of time. Individuals are allocated to prognostic groups based on their progression characteristics (e.g. the decrease 
of eGFR) at the end of the observation period and baseline data are assessed to separate the strata. The internal 
and external validity of the findings however critically depend on the assumption that individuals remain in 
their category of prognosis irrespective of the further follow-up time. In case the course is not linear (e.g. based 
on variable pathophysiology and/or effects of therapy) we can expect patients changing their prognostic group, 
which will directly affect the accuracy of a prognostic biomarker (panel).
The objective of this study was to provide a descriptive analysis of the intra-individual variability in eGFR 
trajectories in early DKD. Common surrogate endpoints used in published biomarker studies (for example  in19–22 
on DKD progression were examined regarding their stability over 5 years of follow-up.
We analyzed data from two independent prospective cohorts. Based on various definitions of the change in 
eGFR between baseline and a specific point during clinical follow- up, patients were allocated to a group with 
a detrimental prognosis. Next, we evaluated how many of these individuals met the respective definition also 
at other time points of follow-up. In case of a stable eGFR trajectory the group with a detrimental prognosis 
should be composed of the same individuals over time whereas intra-individual non-linearity of progression 
will result in the contrary.
Results
Details for participants are presented in supplementary Table S1. Of note, mean baseline eGFR was preserved in 
both groups and decreased by approximately 7 ml/min/1.73m2 during the follow up period.
To analyze the intra-individual variability of eGFR decline, we used the two-point method focusing on the 
percentage of the change of eGFR between baseline and each follow-up visit. Of the 860 individuals selected 
from the PROVALID study, all patients who had a decline of eGFR between baseline and each individual year of 
follow up of ≥ 25, ≥ 30, ≥ 35 or ≥ 40% were identified. Results for the threshold of ≥ 30% eGFR decline are given in 
Table 1, all other (similar) results in supplementary Table S2. The number of individuals reaching the endpoint 
increased continuously from 25 at a one year to 117 at a year 5 comparison, which is compatible with the concept 
that DKD is a progressive disease on a cohort level. On an individual basis, eGFR trajectories were non-linear in 
Table 1.  Intra-individual stability of an eGFR decline ≥ 30% over time. FU follow up. The tables should be read 
as follows: The vertical lines indicate the number and percentage of patients meeting a specific definition of 
eGFR decline over time. For example, 25 individuals of the PROVALID cohort had a decrease of eGFR ≥ 30% 
after one year of follow-up and form the cohort that is followed (100%). Of these, only 6 meet also meet the 
definition of eGFR decline after 2 years of follow-up (24%) (these numbers are given in bold letters). In the 
next line, we used a definition of a decline in eGFR ≥ 30% during the first 2 years of follow-up and identified 
55 individuals (again forming 100% of the population). Of these, only 6 (10.9%) already have lost more than 
30% of baseline eGFR after one year, whereas 26 individuals recovered renal function during the third year 
of follow-up, leaving only 29 (52.7%) individuals persistently meeting the definition of eGFR decline. When 
looking at the diagonal reading, one can see that on a cohort level the number of patients with a loss of 
eGFR ≥ 30% is increasing from 25 to 117 over time.
eGFR decline ≥ 30% from baseline until
1st year of FU 2nd year of FU 3rd year of FU 4th year of FU 5th year of FU
PROVALID (n = 860)
FU1 (n/%) 25 (100) 6 (24.0) 4 (16.0) 4 (16.0) 4 (16.0)
FU2 (n/%) 6 (10.9) 55 (100) 29 (52.7) 20 (36.4) 16 (29.1)
FU3 (n/%) 8 (11.0) 29 (39.7) 73 (100) 44 (60.3) 33 (45.2)
FU4 (n/%) 15 (16.0) 26 (27.7) 44 (46.8) 94 (100) 53 (56.4)
FU5 (n/%) 14 (12.0) 32 (27.4) 44 (37.6) 53 (45.3) 117 (100)
Validation cohort (n = 178)
FU1 (n/%) 5 (100) 4 (80.0) 2 (40.0) 2 (40.0) 2 (40.0)
FU2 (n/%) 4 (36.4) 11 (100) 5 (45.5) 4 (36.4) 4 (36.4)
FU3 (n/%) 2 (33.3) 5 (83.3) 6 (100) 4 (66.7) 4 (66.7)
FU4 (n/%) 4 (20.0) 5 (25.0) 4 (20.0) 20 (100) 13 (65.0)
FU5 (n/%) 4 (16.0) 7 (28.0) 6 (24.0) 13 (52.0) 25 (100)
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many subjects. For example, 73 patients lost more than 30% of eGFR between baseline and follow-up 3. Of these, 
only 8 (10.9%) and 29 (39.7%) already met the definition after 1 and 2 years, which could be explained by slower 
progression in the rest. However, after 4 and 5 years, only 44 (60.3%) and 33 (45.2%) of these individuals again 
were grouped in this category, the remainder obviously partially recovered eGFR after year 3. In the validation 
cohort identical results were obtained (bottom Table 1), but the number of subjects was smaller.
To evaluate if non-linearity of the eGFR trajectories was induced by changes in drug prescriptions, we defined 
a subset of PROVALID participants in whom neither treatment with RAAS blocking agents nor SGLT-2 inhibitors 
was introduced or discontinued during the entire period (n = 552), but similar results were obtained (data for 
a threshold of ≥ 30% eGFR decline are given on top of supplementary Table  S3, details on all other thresholds 
in supplementary Table S4). Even when the analysis was restricted to those individuals, who also had a stable 
prescription of calcium antagonists, diuretics, and non-steroidal anti-inflammatory drugs (n = 277), results did 
not change substantially (bottom supplementary Table S3, but the number of individuals analysed became low.
Many clinical trials use the definition of a “confirmed reduction in eGFR” and we thus looked into the PROV-
ALID cohort to evaluate the impact of allocating only those patients to the group with a detrimental prognosis, 
who had a reduction of ≥ 30% between baseline at two consecutive time points during follow-up. As shown for 
example in Table 2, 29 patients had a reduction in eGFR of ≥ 30% at the second follow-up which was confirmed 
in the third follow-up. Of these however, again only 20 (69%) and 16 (55.2%) also met this endpoint after 4 and 
5 years.
Finally, we defined “rapid progression” as a loss of eGFR of ≥ 5 ml/min/1.73m2/year of follow up (slope 
method). Table 3 shows that this approach also did not define a consistent group over time. For example, 206 
individuals of the PROVALID cohort experienced this eGFR decline at follow-up 3, but only 119 (57.8%), and 80 
(38.8%) also met the definition at follow-up 4 and 5. Results were again similar in the validation cohort (bottom 
Table 3) and for the 552 individuals on stable RAAS and SGLT-2 inhibitor therapy (supplementary Table S5).
To evaluate the impact of baseline eGFR and albuminuria on the individual stability of an eGFR decline ≥ 30% 
or ≥ 5 ml/min/1.73m2/year, we divided participants of the PROVALID cohort into categories of baseline eGFR 
(≥ 60 and < 60 ml/min/1.73m2) or baseline urinary albumin-to-creatinine ratios (UACR, < 30 or ≥ 30 mg/g). 
Results did not change significantly (supplementary Tables S6, S7, S8 and S9), however with small numbers of 
individuals in the groups.
Table 2.  Intra-individual stability of a “confirmed” eGFR decline ≥ 30% over time. FU follow up. Bold 
numbers: number of individuals (%) persistently meeting the definition of eGFR decline over time.
n = 860 Confirmed eGFR decline ≥ 30% from baseline until
1st and 2nd FU 3rd FU 4th FU 5th FU
n (%) 6 (100%) 4 (66.7%) 4 (66.7%) 4 (66.7%)
1st FU 2nd and 3rd FU 4th FU 5th FU
n (%) 4 (13.8%) 29 (100%) 20 (69.0%) 16 (55.2%)
1st FU 2nd FU 3rd and 4th FU 5th FU
n (%) 4 (9.1%) 20 (45.5%) 44 (100%) 33 (75.0%)
1st FU 2nd FU 3rd FU 4th and 5th FU
n (%) 4 (7.5%) 16 (30.2%) 33 (62.3%) 53 (100%)
Table 3.  Intra-individual stability of an eGFR decline ≥ 5 ml/min/1.73m2/year over time. FU follow up. 
Bold numbers: number of individuals (%) persistently meeting the definition of eGFR decline over time. The 
calculation of the slopes is based on linear regressions using at least 3 eGFR observations for each patient. For 
this reason, a comparison between baseline and FU1 is missing in the table.
eGFR decline ≥ 5 ml/min/1.73m2/year until
2nd year of FU 3rd year of FU 4th year of FU 5th year of FU
PROVALID (n = 860)
FU2 (n/%) 288 (100) 169 (58.7) 112 (38.9) 79 (27.4)
FU3 (n/%) 169 (82.0) 206 (100) 119 (57.8) 80 (38.8)
FU4 (n/%) 112 (76.2) 119 (81.0) 147 (100) 87 (59.2)
FU5 (n/%) 79 (74.5) 80 (75.5) 87 (82.1) 106 (100)
Validation cohort (n = 178)
FU2 (n/%) 46 (100) 19 (41.3) 12 (26.1) 10 (21.7)
FU3 (n/%) 19 (79.2) 24 (100) 13 (54.2) 10 (41.7)
FU4 (n/%) 12 (63.2) 13 (68.4) 19 (100) 15 (78.9)
FU5 (n/%) 10 (55.6) 10 (55.6) 15 (83.3) 18 (100)
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Discussion
The rate of progression varies between individuals in chronic kidney  disease10 and especially in  DKD23. This 
observation stimulates research to develop biomarkers able to replace the current albuminuria and eGFR based 
cohort centric probabilistic approach of estimating prognosis by a more deterministic assessment at the level 
of an individual.
One crucial element in implementation of biomarkers is the definition of the endpoint to be predicted. Choos-
ing the incidence of ESRD and/or a doubling serum creatinine is reasonable in more advanced stages of DKD, 
but not absolutely preferred in early phases given the prolonged time of follow up necessary, leaving ample room 
for competing risks. As an alternative, the KDIGO guidelines suggest a decrease of eGFR exceeding 25% or a 
loss of more than 5 ml/min/1.73m2/year to define patients at highest risk and their early identification becomes 
a more realistic aim. Biomarker research in this area conventionally relies on information from observational 
cohorts or interventional trials and allocates individuals to a high risk/fast progression group. Next, baseline data 
are analysed to define a biomarker/a biomarker panel that separates these individuals from controls/individuals 
with slow progression. Unfortunately, the success to predict changes in eGFR by biomarkers hitherto is limited. 
One explanation is their often limited, additional information when used on top of albuminuria and eGFR. This 
could be a consequence of a bad markers selection and much effort focuses on “Omics”-profiling and machine 
learning techniques to advance, but again only little progress has been achieved so far and the cost effectiveness 
remains to be  determined24. In addition, based on our results, we postulate that the failure to identify accurate 
and reliable prognostic biomarkers to decipher inter-individual heterogeneity in DKD progression is due to a 
lack of studies to acknowledge intra-individual variability in progression. Supplementary Tables S10a,b show 
a summary of biomarker studies in type 2 diabetes assessed via Pubmed in June, 2019. For example, Saulnier 
et al.19 explored the prognostic value of midregional-proadrenomedullin (MR-proADM), soluble tumor necrosis 
factor receptor 1 (sTNFR1), and N-terminal prohormone brain natriuretic peptide (NT-proBNP) for a decline 
in eGFR of ≥ 40% during 4.3 years of follow-up or an eGFR annual slope ≥ 5 ml/min/1.73m2/year. Mise et al.20 
analysed the association of urinary levels of glycans binding to six lectins in 675 participants over a follow-up 
period of 4.0 years and a decrease in eGFR of ≥ 30% or dialysis. Chung et al.21 evaluated the predictive value of 
n-3 polyunsaturated fatty acids and interleukin-6 in 676 participants with type 2 diabetes. Renal function decline 
was defined as an eGFR decline of ≥ 25% over a 4-year period. In a sub-analysis of the Nurses’ Health  Study22, 
the association of soluble tumour necrosis factor receptor 2 and an eGFR decline of ≥ 25% over 11 years was 
evaluated. Most of those studies could show a significant association of the analysed biomarker and the renal 
endpoint, but if the patients meeting the defined endpoint are not the same at different points of follow up any 
biomarker defining the group at a specific point in time loses precision at others.
As described above, in our study we were unable to define a group of individuals that over time stably met 
the definition of a poor outcome despite using various, guideline approved endpoint definitions (even a “con-
firmed drop of eGFR”) (Table 4). Variability in intra-individual progression has also been reported by others. 
For example, in the African American Study of Kidney Disease 41.6% of participants exhibited a greater than 
90% probability of having a non-linear trajectory; in 66.1% the probability of non-linearity was > 50%25. We 
do not suggest that an eGFR slope or a percentage drop of eGFR are not valid surrogate endpoints for kidney 
disease progression in clinical trials on a cohort level as recently shown by Inker et al.26, but rather argue that 
their prognostic information content for an individual in early DKD is low. This finding does not preclude bet-
ter performance of markers in later stages of DKD, as the trajectories of renal function loss may be much more 
linear towards end-stage renal disease.
For example, a set of nine biomarkers was selected based on pathophysiological reasoning and measured in 
baseline samples of 1,765 patients recruited into two clinical  trials27. The variability of the annual loss of eGFR 
explained by the biomarkers, indicated by the adjusted  R2 value, was 15% and 34% for patients with eGFR ≥ 60 
and < 60 ml/min/1.73  m2, respectively; variability explained by clinical predictors was 20% and 31% and a com-
bination of both increased the adjusted  R2 to 35% and 64%. In summary, predicting the individual eGFR slope 
seems more feasible in advanced disease but is difficult in individuals with the greatest clinical need, i.e. those 
with a (relatively) preserved renal function.
Interestingly, our results did not change substantially when we analysed only individuals on stable medica-
tion. This is a strong indication that the efficacy of interventions also is variable over time. If confirmed in other 
cohorts this observation not only has to be taken into account when developing biomarkers predicting treatment 
response. It will also mandate a critical appraisal of the current clinical practise of caring for patients with DKD 
as re-assessment of prognosis as well as efficacy of therapy will be needed in regular intervals. This conclusion 
is supported by a publication of Zewinger et al. Measurements of urinary Dickkopf-3 levels, a stress-induced 
Table 4.  Comparison of different methods to assess the individual stability over time of an eGFR decline from 
baseline until FU 3. FU follow up. Bold numbers: number of individuals (%) persistently meeting the definition 
of eGFR decline over time.
PROVALID (n = 860)  ≥ 30% decline from baseline  ≥ 5 ml/min/1.73m2/year Confirmed reduction ≥ 30% in 2 consecutive FUs
FU 2, n (%) 29 (39.7) 169 (82.0) 4 (13.8)
FU 3, n (%) 73 (100) 206 (100) 29 (100)
FU 4, n (%) 44 (60.3) 119 (57.8) 20 (69.0)
FU 5, n (%) 33 (45.2) 80 (38.8) 16 (55.2)
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tubular epithelia-derived pro-fibrotic glycoprotein, in patients with IgA nephropathy predicted eGFR decline 
for the next a maximum of 6 months but, if repeated, also over a prolonged period of  time28.
It could be argued that our results are caused by fluctuations of serum creatinine levels that are not due to 
changes in renal function. However, Hilderink et al. showed that this spontaneous variability leads to fluctua-
tions of eGFR of 13–20%29 only, a value lower than many of our criteria used to define a group of individuals 
with a detrimental prognosis. Nonetheless we could not evaluate the stability of an eGFR decline of ≥ 45 or 50% 
as the patient number became low. This however is a clear indication of a limited clinical practise relevance of 
this definition in early DKD with relatively preserved eGFR. A clear limitation of our study is that the number 
of individuals in our eGFR or albuminuria subgroup analysis is small, but in any case, the results are consistent 
with the other analyses.
Available biomarker studies posthoc defined groups of progressors and non-progressor (inter-individual 
variability) based on either a defined slope of eGFR over time or a percentage of decrease of eGFR over a period 
of 2–5 years. Next, biomarkers were analyzed at baseline to discriminate between the two groups. With this 
approach, adjustment for other covariates at baseline to evaluate the performance of the biomarkers is definitely 
helpful. However, we focus on intra-individual longitudinal variability in progression. This phenomenon ques-
tions the validity of the endpoint and adjustment for baseline factors is not able to handle the problem. However, 
we did a subgroup analysis with patients stratified for albuminuria status at baseline, the most prominent risk 
factor for progression in DKD. As can be seen in supplementary Table S8 the intra-individual variability in the 
changes in eGFR was independent of albuminuria status at baseline. Therefore, we can conclude that the stability 
of the intra-individual change in eGFR over time does not depend on the magnitude of baseline albuminuria.
In summary, our study shows that in early DKD progression, when defined by a (confirmed or non-con-
firmed) decline in eGFR of ≥ 25, ≥ 30, ≥ 35 or ≥ 40% or a loss of ≥ 5 ml/min/1.73m2/year at any point in time 
within a period of 5 years, does not reliably identify individual patients that form a stable group with high risk. 
Therefore, biomarkers predicting the individual risk at a specific point in time in a study are not necessarily also 
accurate at other points in time or in independent cohorts.
Methods
Study population. For evaluating the decline of eGFR in type 2 diabetes we used data from patients 
recruited into the “Prospective cohort study in patients with type 2 diabetes mellitus for validation of biomark-
ers” (PROVALID). Details of the trial are presented  elsewhere30. In summary, the PROVALID database provides 
annual information on medication and the incidence and progression of renal and cardiovascular disease in 
4000 prevalent patients with type 2 diabetes in five European countries (Austria, Hungary, the Netherlands, 
Poland and Scotland) all being taken care at the primary level of healthcare. We selected 860 individuals with 
complete annual follow up information for at least 5 consecutive years. Exclusion criteria were an age < 18 years, 
a BMI < 18 or > 40 kg/m2 and a baseline eGFR value > 150 ml/min/1.73m2. Serum creatinine was determined by 
the IDMS traceable methodology and eGFR was calculated by the CKD-EPI  equation31.
In addition, we had access to a cohort of 768 patients with type 2 diabetes, who attended a medical practice in 
the area of Innsbruck between January 1995 and April 2018 (validation cohort). Further details on this population 
are given  in32. We used the same in- and exclusion criteria as described above and identified 178 individuals. As 
these patients were not included into a study with fixed follow up schedules, the mean time between the visits 
was 1.29 years and the mean total follow up time was 7.7 ± 2.0 years.
For the analysis of variability in eGFR decline we used gender and age for calculation of eGFR, and albuminu-
ria status and medication (RAAS inhibitors, SGLT2 inhibitors, calcium antagonists, diuretics and non steroidal 
anti-inflammatory agents) for stratification.
The PROVALID study and sub-analyses of the study were approved by Institutional Review Boards in all 
participating countries (Austria: Ethics committee of the Medical University Innsbruck, Ethics committee of 
Upper Austria; Poland: Ethics Committee of the Medical University of Silesia; the Netherlands: Medical Ethi-
cal Committee of the University Medical Center Groningen (UMCG); United Kingdom: NHS Research Ethics 
Committee; Hungary: Semmelweis University, Department of Bioethics). In the validation cohort an informed 
consent about the participation was provided by all patients. All study-related interventions were conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice.
Statistics. Surrogate endpoints used to analyze the intra-individual variability in eGFR decline descriptively 
were the same as they were used in a majority of biomarker studies on this topic (supplemental tables S10a,b): 
(1) a percentage decline of eGFR between baseline and each consecutive follow-up visit of more than 25, 30, 35 
or 40% (two-point method) or (2) a loss of eGFR of ≥ 5 ml/min/1.73m2/year (slope method). Regarding (2), we 
applied a standard linear regression model for each individual. In particular, we regressed the individual eGFR 
on a time trend (indication each follow-up measurement) and stored the slope coefficient of each regression.
We next calculated the number of individuals reaching the eGFR surrogate endpoint at a specific year of 
follow up and the percentage of these individuals, that also met the same surrogate endpoint at other follow up 
time points.
As many more recent biomarker studies also use a “confirmed” change in eGFR (loss of a specific amount of 
eGFR at one and another consecutive measurement) we also applied this criterion in a sub-analysis.
To eliminate the impact of changes of treatment on eGFR trajectories we also performed all analyses in 
the PROVALID cohort in a subpopulation of 552 patients, who were receiving or not receiving renin-angio-
tensin aldosterone system (RAAS) blocking agents and SGLT-2 inhibitors during the entire follow up period 
and in 277 individuals in whom also other medications (e.g. diuretics, calcium channel blockers or NSAIDS) 
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were unaltered. In addition, a separate analysis was performed in individuals based on baseline eGFR (< 60 
and ≥ 60 ml/min/1.73m2) and albuminuria status (normo- or micro- and macroalbuminuria).
Finally, the comparison of characteristics between the PROVALID and the validation cohort reported in sup-
plementary Table S1 is based on an unpaired two-sample t-test on equal means. The p-value in the last column 
is based on a two-sided test. All the empirical analysis is carried out with Stata (version 16).
Data availability
The data that support the findings of this study are available from the PROVALID investigators and from the 
Medical Center Hentschelhof, but restrictions apply to the availability of these data, which were used under 
license for the current study, and so are not publicly available. Data are however available from the authors upon 
reasonable request and with permission of the PROVALID investigators and the Medical Center Hentschelhof.
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